Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine
The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.
“We know clinically that often patients will take a second dose of medication. Especially if they felt that they were starting to feel better but didn’t quite get the effect they were hoping for, they tend to re-dose.”
At the now-canceled
That second analysis, conducted by Jessica Ailani, MD, FAHS, director, MedStar Georgetown Headache Center, and associate professor of neurology, MedStar Georgetown University Hospital, and colleagues, showed that ubrogepant is the first and only treatment to demonstrate statistically higher rates of pain freedom at second dose compared to placebo, without additional safety concerns identified.2
To find out more about what the data show, how they should be interpreted clinically, and the significance of patients having success with a second dose, NeurologyLive connected virtually with Ailani to gain her perspective on the results.
­
For more AAN coverage,
REFERENCES
1. Lipton R, Dodick D, Goadsby PJ, et al. Ubrogepant is Effective in the Acute Treatment of Migraine with Mild Pain. Neurology. 2020;94(15 Suppl): 4726.
2. Ailani J, Blumenfeld A, Klein B, et al. An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine. Neurology. 2020;94(15 Suppl): 166.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
